ANIX - Company ID 0000715446
The table below shows Anixa Biosciences Inc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $1.10M | $1.05M | $1.32M | $1.55M | $1.93M | $1.65M |
| SG&A |
Anixa Biosciences Inc reported annual revenue of $210.00K for fiscal year 2024. That is up 0.0% from $210.00K in fiscal 2023. Over the 10 fiscal years shown, annual revenue declined from $388.85K (FY 2013) to $210.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.61M |
| $1.38M |
| $1.68M |
| $1.83M |
| $1.67M |
| $1.82M |
| Operating income | -$2.72M | -$2.44M | -$3.00M | -$3.39M | -$3.59M | -$3.47M |
| Income tax | - | - | - | - | - | - |
| Net income | -$2.56M | -$2.26M | -$2.79M | -$3.18M | -$3.28M | -$3.14M |
| EPS (diluted) | -$0.08 | -$0.07 | -$0.09 | -$0.10 | -$0.10 | -$0.10 |